Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-Adapted COVID-19 Vaccine in the EU
Pfizer and BioNTech have received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the
Read more
Latest
New 3D Cell-based Model Unveils Insights on Immune Cells in Alzheimer’s Disease
Researchers have devised a novel human 3D model for Alzheimer’s Disease, enabling the study of immune cell involvement in the
Read more
GSK’s ADC Blenrep Cuts Risk of Multiple Myeloma Progression by Nearly 50% in Phase III Trial
British pharma giant GSK has announced positive results from an interim analysis of the DREAMM-8 phase III head-to-head trial evaluating Blenrep (belantamab
Read more
Sanofi, Formation Bio and OpenAI Forge First-in-class AI Collaboration
In a forward-thinking move, Sanofi, Formation Bio, and OpenAI have joined forces to harness the power of artificial intelligence in
Read more
Celltrion’s Omlyclo Gets EC Green Light for Allergic Conditions
The approval is supported by robust clinical evidence, including results from a global Phase III trial. Omlyclo® is the first
Read more
Takeda Inks $2.2 Billion License Deal for AC Immune’s Alzheimer’s Immunotherapy
Takeda has secured an exclusive global option and license agreement for AC Immune’s promising active immunotherapy targeting amyloid beta for
Read more
Boehringer and Walgreens Partner to Improve Diversity in Clinical Trials
In this partnership, Boehringer Ingelheim will utilise specific US-based pharmacy store chain Walgreens sites for clinical trials focusing on individuals
Read more
BMS and Cellares Enter $380m CAR T Cell Therapy Capacity & Supply Deal
Bristol Myers Squibb (BMS) announced on Monday it has entered a worldwide capacity reservation and supply agreement with the California-headquartered Integrated
Read more
NIH Researchers Improve Cancer Drug Response Prediction Using scRNA-seq Data AI Model
In a proof-of-concept study, researchers at the National Institutes of Health (NIH) explored the feasibility of employing transfer learning, a machine
Read more
Ventus’ NLRP3 Inhibitor Shows Potential for CNS Diseases in Phase 1 Trial
Ventus Therapeutics, a US-based clinical-stage biopharmaceutical company leveraging its exclusive structural biology and computational chemistry platform, ReSOLVE™, has disclosed promising
Read more